LNP3794 in patients with Advanced Solid Tumours having Mutations
Research type
Research Study
Full title
A Phase 1 Study of LNP3794 in Patients with Advanced Solid Tumors having RAS/BRAF Mutations
IRAS ID
157025
Contact name
Udai Banerji
Contact email
Sponsor organisation
Lupin Limited
Eudract number
2014-001536-10
Research summary
LNP3794 is an experimental drug that is being developed for the treatment of various types of cancer such as skin cancer, pancreatic cancer, non-small cell lung carcinoma, colorectal cancer, or thyroid cancer. It acts by blocking an exnzyme (a protein) called MEK, important for the growth of tumour cells. The enzyme MEK has been shown to be activated in solid tumours with mutations in the BRAF and RAS genes, which are involved in cancer cell growth.
This is a Phase I study. The purpose of this study is to determine the highest safe dose (maximum tolerated dose) of LNP3794 when administered orally to adult patients with advanced solid tumour that have progressed despite standard therapy, or for which no standard therapy exists.
A total of approximately 17 patients will participate in this study at multiple locations internationally. The study will be run at approximately 2 centres in the UK and is sponsored by Lupin Ltd.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
14/LO/1171
Date of REC Opinion
7 Aug 2014
REC opinion
Further Information Favourable Opinion